Evidence-based · Peptides
Steady State Explained: Why It Takes ~4-5 Half-Lives
Steady state is when what you take in each interval equals what you clear. It arrives after ~4-5 half-lives, a timeline set by half-life alone, not the dose.
Part ofThe Research-Peptide Directory→When you take a compound on a repeating schedule, its level in your body does not jump straight to a stable value. It climbs, dose after dose, and then flattens out. That plateau is steady state, the point where the amount you take in during each interval is balanced by the amount your body clears. The single most useful fact about it is that reaching it takes roughly four to five half-lives, and that timeline is set by half-life alone. Not by the dose. Not by how you space the doses. You can watch this play out for any half-life and interval you enter in the Dose Interval Visualizer.
What steady state is
Every dose you take starts declining the moment it enters circulation. If you take the next dose before the previous one has fully cleared, some carries over. Levels build. But clearance is proportional to how much is present: the more compound in your system, the faster you eliminate it in absolute terms. So as levels rise, elimination speeds up to match intake, until the two are in balance. At that point the concentration stops trending upward and cycles between a peak (just after a dose) and a trough (just before the next one), repeating the same pattern indefinitely.
Steady state is not a single flat line. It is a repeating saw-tooth (the same rise and fall every interval) whose average, peak, and trough no longer change from one dose to the next.
Why ~4-5 half-lives, and why dose doesn’t matter
The approach to steady state follows the same exponential curve as the decay of a single dose, just running in reverse. After one half-life you are about halfway there; after two, about three-quarters; after three, roughly 88%; after four, about 94%; after five, about 97%. By convention, four to five half-lives is treated as “there” because the remaining gap is clinically trivial.
| Half-lives elapsed | % of steady state reached |
|---|---|
| 1 | ~50% |
| 2 | ~75% |
| 3 | ~88% |
| 4 | ~94% |
| 5 | ~97% |
A larger dose does not get you to steady state faster. Double the dose and every point on the curve doubles (the trough, the peak, the plateau), but the shape of the climb is identical, so it still takes the same 4-5 half-lives to arrive. A bigger dose raises the ceiling; it does not shorten the elevator ride. The same holds for the dosing interval: change how often you dose and you change how high the plateau sits and how much levels swing, but the time to reach it still tracks the half-life. This independence from dose is one of the most reliable results in pharmacokinetics.
What this means in practice
The 4-5 half-life rule quietly explains a lot of real-world experience.
- A weekly compound with a ~1-week half-life takes about a month to plateau. Semaglutide is the textbook case: a roughly one-week half-life means around five weeks of consistent dosing before levels stabilize. Effects (and some side effects) can keep evolving over that window even at a fixed dose. See Peptide Half-Life, Explained for why half-lives vary so widely across the GLP-1 family.
- A short-half-life compound reaches steady state in days, not weeks. Something cleared in hours will plateau within a day or two of regular dosing.
- Washout mirrors the climb. Stop dosing and it takes the same 4-5 half-lives for the compound to leave your system. That symmetry is why what happens when you stop a GLP-1 unfolds over weeks, not overnight.
- “I don’t feel it yet” is often just kinetics. If you are two doses into a long-half-life protocol, you may be partway up the curve, not at the level the schedule is designed to reach.
Steady state vs. the accumulation ratio
Two distinct ideas often get tangled. Time to steady state answers “how long until levels stabilize?” and the answer is always about 4-5 half-lives. The accumulation ratio answers a different question: “how much higher is the steady-state level than a single dose?” That one depends on the relationship between half-life and dosing interval. Dose frequently relative to how fast you clear, and a lot carries over; dose far apart and almost nothing does. That mechanism gets its own treatment in Drug Accumulation. The visualizer reports both numbers side by side so you can see that a compound can reach steady state quickly yet still accumulate a great deal, or slowly and barely accumulate at all.
The takeaway
Steady state is the plateau where intake and clearance balance, and getting there takes about four to five half-lives no matter how big the dose or how it is spaced. Dose and interval set where the plateau lands; half-life sets when you arrive, and how long the compound lingers once you stop. If a protocol’s effects seem to keep shifting for weeks, you are probably still climbing that curve.
Model it for any compound with the Dose Interval Visualizer, and pair it with the Peptide Half-Life Visualizer to see the single-dose decay behind the plateau.
This article is educational and not medical advice. Many research peptides are not approved for human use; dosing decisions belong with a qualified clinician.
Sources
References
Compounds in this article
Stay current
Get evidence-based briefings in your inbox.